MIRA Pharmaceuticals reported financial results for the quarter ended June 30, 2025. Revenue was $0, on par with our estimate. Q2 2025 net loss was $1.54 million, or $(0.09) per share on 16.99 million weighted average common shares outstanding, beating our $(0.15) EPS estimate due to lower than expected operating costs.